Theravance Biopharma to Present at the Leerink Global Healthcare Conference
(firmenpresse) - DUBLIN, IRELAND -- (Marketwired) -- 02/03/16 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Brett Haumann, Senior Vice President, Clinical Development is scheduled to present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11, 2016, at 8:55 a.m. EST. The conference will be held from February 10-11 in New York at the Waldorf Astoria, New York.
The presentation will be webcast live and can be reached by visiting the Investor Relations section of Theravance Biopharma''s website at , under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
The mission of Theravance Biopharma (NASDAQ: TBPH) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.
Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates ("GSK") pursuant to its agreements with Innoviva, Inc. (formerly Theravance, Inc.) relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium and vilanterol (the "Closed Triple").
With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.
For more information, please visit .
THERAVANCE®, the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE® and VIBATIV® are registered trademarks of the Theravance Biopharma group of companies.
Renee Gala
Chief Financial Officer
650-808-4045
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2016 - 15:30 Uhr
Sprache: Deutsch
News-ID 1413127
Anzahl Zeichen: 2996
contact information:
Contact person:
Town:
DUBLIN, IRELAND
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Theravance Biopharma to Present at the Leerink Global Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Theravance Biopharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
